Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata

Loading news article.

Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata | WAPE

Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata

Article summary

Related companies

Comments —